文献速递乳腺癌

激素敏感乳腺癌辅助治疗:阿那曲唑、依西美坦、来曲唑及其起始时机的FATA-GIM3三期随机试验

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-02-23

FATA-GIM3是一项多中心开放标签三期随机试验,入组3697例激素受体阳性早期乳腺癌绝经后患者,比较三种芳香化酶抑制剂(AI)起始或他莫昔芬2年后转换策略。

要点

  • AI起始5年不优于他莫昔芬2年后AI 3年,5年DFS差异未达预设2%优效界值。
  • 选择方案应综合患者偏好、耐受性与经济因素。

核心结论

  • 5年AI治疗不优于他莫昔芬2年后序贯3年AI;三种AI之间疗效无优劣。

研究设计与样本

  • 多中心、开放标签、随机三期试验,入组3697例激素受体阳性早期乳腺癌绝经后患者,按1:1随机分入六组(三种AI起始5年或他莫昔芬2年后AI 3年)。
  • 随机采用计算机最小化法,按ER、PR、HER2状态、既往化疗及病理淋巴结状态分层;主要终点为无病生存,主要疗效分析为意向治疗。

主要发现

  • 中位随访60个月(IQR 46-72),共报告401例无病生存事件:转换策略211/1850例(11%),起始策略190/1847例(10%)。
  • 未发生意外严重不良反应或治疗相关死亡;3-4级肌肉骨骼事件在转换策略130/1761例(7%)、起始策略128/1766例(7%)。
  • 1级肌肉骨骼事件起始策略更常见:924/1766例(52%)vs 745/1761例(42%);其余3-4级不良事件两组均低于2%。

关键数值与推荐

  • 主要终点优效界值:起始策略相对转换策略5年无病生存率差异需达2%。

临床怎么用

  • 激素受体阳性早期乳腺癌绝经后患者可选择起始AI 5年或他莫昔芬2年后AI 3年,两者疗效相近。
  • 三种AI疗效相当,临床决策应结合患者偏好、耐受性(如肌肉骨骼症状)及经济条件选择。

局限性

  • 开放标签设计,患者与医生均未设盲。
  • 随访仍在进行,中位随访60个月,长期结局待进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. METHODS: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. FINDINGS: Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46-72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7-90·0) with the switch strategy and 89·8% (88·2-91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73-1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9-91·7) with anastrozole (124 events), 88·0% (85·8-89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3-4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3-4 adverse events occurred in less than 2% of patients in either group. INTERPRETATION: 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting. FUNDING: Italian Drug Agency.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. De Placido S, Gallo C, De Laurentiis M, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018. PMID: 29482983. doi:10.1016/S1470-2045(18)30116-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。